Galectin-1 as a potent target for cancer therapy: Role in the tumor microenvironment

Cancer and Metastasis Reviews

Volumn 31, Issue 3-4, 2012, Pages 763-778

  Ito, Koichi ^a   Stannard, Kimberley ^a,b   Gabutero, Elwyn ^a   Clark, Amanda M ^a   Neo, Shi Yong ^c   Onturk, Selda ^a   Blanchard, Helen ^a   Ralph, Stephen J ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b GREENSLOPES PRIVATE HOSPITAL   (Australia)

^c SINGAPORE POLYTECHNIC   (Singapore)

Author keywords

Galectin 1; Hypoxia; Immunosuppression; Metastasis; Tumor angiogenesis

Indexed keywords

ALPHA GALACTOMANNAN; ANGINEX; ANGIOGENESIS INHIBITOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GALECTIN 1; GCS 100; GLYCAN; PECTIN; THIODIGALACTOSIDE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CELL HYPOXIA; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE FUNCTION; METASTASIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; TUMOR MICROENVIRONMENT;

ANIMALS; CELL HYPOXIA; GALECTIN 1; HUMANS; IMMUNE TOLERANCE; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; T-LYMPHOCYTES; THIOGALACTOSIDES; TUMOR MICROENVIRONMENT;

EID: 84867990611     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-012-9388-2     Document Type: Review

References (152)

1. Barondes, S. H.; Castronovo, V.; Cooper, D. N.; Cummings, R. D.; Drickamer, K.; Feizi, T.; et al. (1994). Galectins: a family of animal beta-galactoside-binding lectins. Cell, 76(4), 597-598.
2. Cooper, D. N. (2002). Galectinomics: finding themes in complexity. Biochimica et Biophysica Acta, 1572(2-3), 209-231.
3. Yang, R. Y.; Rabinovich, G. A.; & Liu, F. T. (2008). Galectins: structure, function and therapeutic potential. Expert Reviews in Molecular Medicine, 10, e17.
4. Than, N. G.; Romero, R.; Erez, O.; Weckle, A.; Tarca, A. L.; Hotra, J.; et al. (2008). Emergence of hormonal and redox regulation of galectin-1 in placental mammals: implication in maternal-fetal immune tolerance. Proceedings of the National Academy of Sciences of the United States of America, 105(41), 15819-15824.
5. Bourne, Y.; Bolgiano, B.; Nesa, M. P.; Penfold, P.; Johnson, D.; Feizi, T.; et al. (1994). Crystallization and preliminary X-ray diffraction studies of the soluble 14 kDa beta-galactoside-binding lectin from bovine heart. Journal of Molecular Biology, 235(2), 787-789.
6. Kadoya, T.; & Horie, H. (2005). Structural and functional studies of galectin-1: a novel axonal regeneration-promoting activity for oxidized galectin-1. Current Drug Targets, 6(4), 375-383.
7. Scott, S. A.; Bugarcic, A.; & Blanchard, H. (2009). Characterisation of oxidized recombinant human galectin-1. Protein and Peptide Letters, 16(10), 1249-1255.
8. Inagaki, Y.; Sohma, Y.; Horie, H.; Nozawa, R.; & Kadoya, T. (2000). Oxidized galectin-1 promotes axonal regeneration in peripheral nerves but does not possess lectin properties. European Journal of Biochemistry, 267(10), 2955-2964.
9. Horie, H.; Kadoya, T.; Hikawa, N.; Sango, K.; Inoue, H.; Takeshita, K.; et al. (2004). Oxidized galectin-1 stimulates macrophages to promote axonal regeneration in peripheral nerves after axotomy. The Journal of Neuroscience, 24(8), 1873-1880.
10. Demydenko, D.; & Berest, I. (2009). Expression of galectin-1 in malignant tumors. Experimental Oncology, 31(2), 74-79.
11. Thijssen, V. L.; Poirier, F.; Baum, L. G.; & Griffioen, A. W. (2007). Galectins in the tumor endothelium: opportunities for combined cancer therapy. Blood, 110(8), 2819-2827.
12. Garin, M. I.; Chu, C. C.; Golshayan, D.; Cernuda-Morollon, E.; Wait, R.; & Lechler, R. I. (2007). Galectin-1: a key effector of regulation mediated by CD4+ CD25+ T cells. Blood, 109(5), 2058-2065.
13. Camby, I.; Le Mercier, M.; Lefranc, F.; & Kiss, R. (2006). Galectin-1: a small protein with major functions. Glycobiology, 16(11), 137R-157R.
14. Honjo, Y.; Inohara, H.; Akahani, S.; Yoshii, T.; Takenaka, Y.; Yoshida, J.; et al. (2000). Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. Clinical Cancer Research, 6(12), 4635-4640.
15. Cho, M.; & Cummings, R. D. (1995). Galectin-1, a beta-galactoside- binding lectin in Chinese hamster ovary cells. II. Localization and biosynthesis. Journal of Biological Chemistry, 270(10), 5207-5212.
16. Cho, M.; & Cummings, R. D. (1995). Galectin-1, a beta-galactoside- binding lectin in Chinese hamster ovary cells. I. Physical and chemical characterization. The Journal of Biological Chemistry, 270(10), 5198-5206.
17. Inohara, H.; Akahani, S.; & Raz, A. (1998). Galectin-3 stimulates cell proliferation. Experimental Cell Research, 245(2), 294-302.
18. Baptiste, T. A.; James, A.; Saria, M.; & Ochieng, J. (2007). Mechano-transduction mediated secretion and uptake of galectin-3 in breast carcinoma cells: implications in the extracellular functions of the lectin. Experimental Cell Research, 313(4), 652-664.
19. Satelli, A.; Rao, P. S.; Gupta, P. K.; Lockman, P. R.; Srivenugopal, K. S.; & Rao, U. S. (2008). Varied expression and localization of multiple galectins in different cancer cell lines. Oncology Reports, 19(3), 587-594.
20. Nickel, W. (2005). Unconventional secretory routes: direct protein export across the plasma membrane of mammalian cells. Traffic, 6(8), 607-614.
21. Watanabe, M.; Takemasa, I.; Kaneko, N.; Yokoyama, Y.; Matsuo, E.; Iwasa, S.; et al. (2011). Clinical significance of circulating galectins as colorectal cancer markers. Oncology Reports, 25(5), 1217-1226.
22. Carlsson, M. C.; Cederfur, C.; Schaar, V.; Balog, C. I.; Lepur, A.; Touret, F.; et al. (2011). Galectin-1-binding glycoforms of haptoglobin with altered intracellular trafficking, and increase in metastatic breast cancer patients. PLoS One, 6(10), e26560.
23. Saussez, S.; Lorfevre, F.; Lequeux, T.; Laurent, G.; Chantrain, G.; Vertongen, F.; et al. (2008). The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy. Oral Oncology, 44(1), 86-93.
24. Saussez, S.; Glinoer, D.; Chantrain, G.; Pattou, F.; Carnaille, B.; Andre, S.; et al. (2008). Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease. Thyroid, 18(7), 705-712.
25. Barrow, H.; Guo, X.; Wandall, H. H.; Pedersen, J. W.; Fu, B.; Zhao, Q.; et al. (2011). Serum galectins -2, -4 and -8 are greatly increased in colon and breast cancer patients and promote cancer cell adhesion to blood vascular endothelium. Clinical Cancer Research, 15;17(22):7035-7046
26. Pacienza, N.; Pozner, R. G.; Bianco, G. A.; D'Atri, L. P.; Croci, D. O.; Negrotto, S.; et al. (2008). The immunoregulatory glycan-binding protein galectin-1 triggers human platelet activation. The FASEB Journal, 22(4), 1113-1123.
27. Chiang, W. F.; Liu, S. Y.; Fang, L. Y.; Lin, C. N.; Wu, M. H.; Chen, Y. C.; et al. (2008). Overexpression of galectin-1 at the tumor invasion front is associated with poor prognosis in early-stage oral squamous cell carcinoma. Oral Oncology, 44(4), 325-334.
28. Kim, H. J.; Jeon, H. K.; Cho, Y. J.; Park, Y. A.; Choi, J. J.; Do, I. G.; et al. (2012). High galectin-1 expression correlates with poor prognosis and is involved in epithelial ovarian cancer proliferation and invasion. European Journal Cancer (in press)
29. Saussez, S.; Cucu, D. R.; Decaestecker, C.; Chevalier, D.; Kaltner, H.; Andre, S.; et al. (2006). Galectin 7 (p53-induced gene 1): a new prognostic predictor of recurrence and survival in stage IV hypopharyngeal cancer. Annals of Surgical Oncology, 13(7), 999-1009.
30. Perillo, N. L.; Pace, K. E.; Seilhamer, J. J.; & Baum, L. G. (1995). Apoptosis of T cells mediated by galectin-1. Nature, 378(6558), 736-739.
31. Rubinstein, N.; Ilarregui, J. M.; Toscano, M. A.; & Rabinovich, G. A. (2004). The role of galectins in the initiation, amplification and resolution of the inflammatory response. Tissue Antigens, 64(1), 1-12.
32. Grigorian, A.; Torossian, S.; & Demetriou, M. (2009). T-cell growth, cell surface organization, and the galectin-glycoprotein lattice. Immunology Reviews, 230(1), 232-246.
33. Nguyen, J. T.; Evans, D. P.; Galvan, M.; Pace, K. E.; Leitenberg, D.; Bui, T. N.; et al. (2001). CD45 modulates galectin-1-induced T cell death: regulation by expression of core 2 O-glycans. The Journal of Immunology, 167(10), 5697-5707.
34. Pace, K. E.; Hahn, H. P.; Pang, M.; Nguyen, J. T.; & Baum, L. G. (2000). CD7 delivers a pro-apoptotic signal during galectin-1-induced T cell death. The Journal of Immunology, 165(5), 2331-2334.
35. Hernandez, J. D.; Nguyen, J. T.; He, J.; Wang, W.; Ardman, B.; Green, J. M.; et al. (2006). Galectin-1 binds different CD43 glycoforms to cluster CD43 and regulate T cell death. The Journal of Immunology, 177(8), 5328-5336.
36. Lange, F.; Brandt, B.; Tiedge, M.; Jonas, L.; Jeschke, U.; Pohland, R.; et al. (2009). Galectin-1 induced activation of the mitochondrial apoptotic pathway: evidence for a connection between death-receptor and mitochondrial pathways in human Jurkat T lymphocytes. Histochemistry and Cell Biology, 132(2), 211-223.
37. Brandt, B.; Abou-Eladab, E. F.; Tiedge, M.; & Walzel, H. (2010). Role of the JNK/c-Jun/AP-1 signaling pathway in galectin-1-induced T-cell death. Cell Death Diseases, 1, e23.
38. Vespa, G. N.; Lewis, L. A.; Kozak, K. R.; Moran, M.; Nguyen, J. T.; Baum, L. G.; et al. (1999). Galectin-1 specifically modulates TCR signals to enhance TCR apoptosis but inhibit IL-2 production and proliferation. The Journal of Immunology, 162(2), 799-806.
39. Chung, C. D.; Patel, V. P.; Moran, M.; Lewis, L. A.; & Miceli, M. C. (2000). Galectin-1 induces partial TCR zeta-chain phosphorylation and antagonizes processive TCR signal transduction. The Journal of Immunology, 165(7), 3722-3729.
40. Matarrese, P.; Tinari, A.; Mormone, E.; Bianco, G. A.; Toscano, M. A.; Ascione, B.; et al. (2005). Galectin-1 sensitizes resting human T lymphocytes to Fas (CD95)-mediated cell death via mitochondrial hyperpolarization, budding, and fission. The Journal of Biological Chemistry, 280(8), 6969-6985.
41. Sturm, A.; Lensch, M.; Andre, S.; Kaltner, H.; Wiedenmann, B.; Rosewicz, S.; et al. (2004). Human galectin-2: novel inducer of T cell apoptosis with distinct profile of caspase activation. The Journal of Immunology, 173(6), 3825-3837.
42. Hahn, H. P.; Pang, M.; He, J.; Hernandez, J. D.; Yang, R. Y.; Li, L. Y.; et al. (2004). Galectin-1 induces nuclear translocation of endonuclease G in caspase- and cytochrome c-independent T cell death. Cell Death and Differentiation, 11(12), 1277-1286.
43. Yang, R. Y.; Hsu, D. K.; & Liu, F. T. (1996). Expression of galectin-3 modulates T-cell growth and apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 93(13), 6737-6742.
44. Fukumori, T.; Takenaka, Y.; Yoshii, T.; Kim, H. R.; Hogan, V.; Inohara, H.; et al. (2003). CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Research, 63(23), 8302-8311.
45. Amano, M.; Galvan, M.; He, J.; & Baum, L. G. (2003). The ST6Gal I sialyltransferase selectively modifies N-glycans on CD45 to negatively regulate galectin-1-induced CD45 clustering, phosphatase modulation, and T cell death. The Journal of Biological Chemistry, 278(9), 7469-7475.
46. Lau, K. S.; Partridge, E. A.; Grigorian, A.; Silvescu, C. I.; Reinhold, V. N.; Demetriou, M.; et al. (2007). Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell, 129(1), 123-134.
47. Juszczynski, P.; Ouyang, J.; Monti, S.; Rodig, S. J.; Takeyama, K.; Abramson, J.; et al. (2007). The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 104(32), 13134-13139.
48. Toscano, M. A.; Bianco, G. A.; Ilarregui, J. M.; Croci, D. O.; Correale, J.; Hernandez, J. D.; et al. (2007). Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nature Immunology, 8(8), 825-834.
49. Toscano, M. A.; Commodaro, A. G.; Ilarregui, J. M.; Bianco, G. A.; Liberman, A.; Serra, H. M.; et al. (2006). Galectin-1 suppresses autoimmune retinal disease by promoting concomitant Th2- and T regulatory-mediated anti-inflammatory responses. The Journal of Immunology, 176(10), 6323-6332.
50. Harrington, L. E.; Galvan, M.; Baum, L. G.; Altman, J. D.; & Ahmed, R. (2000). Differentiating between memory and effector CD8 T cells by altered expression of cell surface O-glycans. The Journal of Experimental Medicine, 191(7), 1241-1246.
51. Galvan, M.; Tsuboi, S.; Fukuda, M.; & Baum, L. G. (2000). Expression of a specific glycosyltransferase enzyme regulates T cell death mediated by galectin-1. The Journal of Biological Chemistry, 275(22), 16730-16737.
52. Ito, K.; Scott, S. A.; Cutler, S.; Dong, L. F.; Neuzil, J.; Blanchard, H.; et al. (2011). Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress. [Research Support, Non-U.S. Gov't]. Angiogenesis, 14(3), 293-307.
53. Banh, A.; Zhang, J.; Cao, H.; Bouley, D. M.; Kwok, S.; Kong, C.; et al. (2011). Tumor Galectin-1 mediates tumor growth and metastasis through regulation of T-cell apoptosis. Cancer Research, 71(13), 4423-4431.
54. Hamzah, J.; Jugold, M.; Kiessling, F.; Rigby, P.; Manzur, M.; Marti, H. H.; et al. (2008). Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature, 453(7193), 410-414.
55. Goel, S.; Duda, D. G.; Xu, L.; Munn, L. L.; Boucher, Y.; Fukumura, D.; et al. (2011). Normalization of the vasculature for treatment of cancer and other diseases. Physiological Reviews, 91(3), 1071-1121.
56. Shrimali, R. K.; Yu, Z.; Theoret, M. R.; Chinnasamy, D.; Restifo, N. P.; & Rosenberg, S. A. (2010). Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Research, 70(15), 6171-6180.
57. Griffioen, A. W.; & Molema, G. (2000). Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacological Reviews, 52(2), 237-268.
58. Tozer, G. M.; Kanthou, C.; & Baguley, B. C. (2005). Disrupting tumour blood vessels. Nature Reviews Cancer, 5(6), 423-435.
59. Castermans, K.; & Griffioen, A. W. (2007). Tumor blood vessels, a difficult hurdle for infiltrating leukocytes. Biochimica et Biophysica Acta, 1776(2), 160-174.
60. Thijssen, V. L.; Hulsmans, S.; & Griffioen, A. W. (2008). The galectin profile of the endothelium: altered expression and localization in activated and tumor endothelial cells. The American Journal of Pathology, 172(2), 545-553.
61. Thijssen, V. L.; Barkan, B.; Shoji, H.; Aries, I. M.; Mathieu, V.; Deltour, L.; et al. (2010). Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Research, 70(15), 6216-6224.
62. Le Mercier, M.; Fortin, S.; Mathieu, V.; Roland, I.; Spiegl-Kreinecker, S.; Haibe-Kains, B.; et al. (2009). Galectin 1 proangiogenic and promigratory effects in the Hs683 oligodendroglioma model are partly mediated through the control of BEX2 expression. Neoplasia, 11(5), 485-496.
63. van den Brule, F.; Califice, S.; Garnier, F.; Fernandez, P. L.; Berchuck, A.; & Castronovo, V. (2003). Galectin-1 accumulation in the ovary carcinoma peritumoral stroma is induced by ovary carcinoma cells and affects both cancer cell proliferation and adhesion to laminin-1 and fibronectin. Laboratory Investigation, 83(3), 377-386.
64. Kawano, T.; Takasaki, S.; Tao, T. W.; & Kobata, A. (1993). Altered glycosylation of beta 1 integrins associated with reduced adhesiveness to fibronectin and laminin. International Journal of Cancer, 53(1), 91-96.
65. Shintani, Y.; Takashima, S.; Asano, Y.; Kato, H.; Liao, Y.; Yamazaki, S.; et al. (2006). Glycosaminoglycan modification of neuropilin-1 modulates VEGFR2 signaling. The EMBO Journal, 25(13), 3045-3055.
66. Pellet-Many, C.; Frankel, P.; Evans, I. M.; Herzog, B.; Junemann-Ramirez, M.; & Zachary, I. C. (2011). Neuropilin-1 mediates PDGF stimulation of vascular smooth muscle cell migration and signalling via p130Cas. The Biochemical Journal, 435(3), 609-618.
67. Hsieh, S. H.; Ying, N. W.; Wu, M. H.; Chiang, W. F.; Hsu, C. L.; Wong, T. Y.; et al. (2008). Galectin-1, a novel ligand of neuropilin-1, activates VEGFR-2 signaling and modulates the migration of vascular endothelial cells. Oncogene, 27(26), 3746-3753.
68. Sugahara, K. N.; Teesalu, T.; Karmali, P. P.; Kotamraju, V. R.; Agemy, L.; Greenwald, D. R.; et al. (2010). Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science, 328(5981), 1031-1035.
69. Semenza, G. L. (2007). Hypoxia and cancer. Cancer and Metastasis Reviews, 26(2), 223-224.
70. Brown, N. S.; & Bicknell, R. (2001). Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Research, 3(5), 323-327.
71. Matsumoto, S.; Yasui, H.; Mitchell, J. B.; & Krishna, M. C. (2010). Imaging cycling tumor hypoxia. Cancer Research, 70(24), 10019-10023.
72. Martinive, P.; Defresne, F.; Bouzin, C.; Saliez, J.; Lair, F.; Grégoire, V.; et al. (2006). Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies. Cancer Research, 66(24), 11736-11744.
73. Dewhirst, M. W.; Cao, Y.; & Moeller, B. (2008). Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nature Reviews Cancer, 8(6), 425-437.
74. Vaupel, P. (2008). Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. The Oncologist, 13(Suppl 3), 21-26.
75. Palazon, A.; Aragones Lopez, J.; Morales-Kastresana, A.; Ortiz Del Landazuri, M.; & Melero, I. J. (2012). Molecular pathways: hypoxia response in immune cells fighting or promoting cancer. Clin Cancer Res, 18, 1207-1213.
76. Lukashev, D.; Klebanov, B.; Kojima, H.; Grinberg, A.; Ohta, A.; Berenfeld, L.; et al. (2006). Cutting edge: hypoxia-inducible factor 1alpha and its activation-inducible short isoform I.1 negatively regulate functions of CD4+ and CD8+ T lymphocytes. The Journal of Immunology, 177(8), 4962-4965.
77. Noman, M. Z.; Buart, S.; Van Pelt, J.; Richon, C.; Hasmim, M.; Leleu, N.; et al. (2009). The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. The Journal of Immunology, 182(6), 3510-3521.
78. Eltzschig, H. K.; Thompson, L. F.; Karhausen, J.; Cotta, R. J.; Ibla, J. C.; Robson, S. C.; et al. (2004). Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. Blood, 104(13), 3986-3992.
79. Ohta, A.; Gorelik, E.; Prasad, S. J.; Ronchese, F.; Lukashev, D.; Wong, M. K.; et al. (2006). A2A adenosine receptor protects tumors from antitumor T cells. Proceedings of the National Academy of Sciences of the United States of America, 103(35), 13132-13137.
80. Facciabene, A.; Peng, X.; Hagemann, I. S.; Balint, K.; Barchetti, A.; Wang, L. P.; et al. (2011). Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature, 475(7355), 226-230.
81. Zhao, X. Y.; Chen, T. T.; Xia, L.; Guo, M.; Xu, Y.; Yue, F.; et al. (2010). Hypoxia inducible factor-1 mediates expression of galectin-1: the potential role in migration/invasion of colorectal cancer cells. Carcinogenesis, 31(8), 1367-1375.
82. Le, Q. T.; Shi, G.; Cao, H.; Nelson, D. W.; Wang, Y.; Chen, E. Y.; et al. (2005). Galectin-1: a link between tumor hypoxia and tumor immune privilege. Journal of Clinical Oncology, 23(35), 8932-8941.
83. Olbryt, M.; Habryka, A.; Tyszkiewicz, T.; Rusin, A.; Cichon, T.; Jarzab, M.; et al. (2011). Melanoma-associated genes, MXI1, FN1, and NME1, are hypoxia responsive in murine and human melanoma cells. Melanoma Research, 21(5), 417-425.
84. Gamrekelashvili, J.; Kruger, C.; von Wasielewski, R.; Hoffmann, M.; Huster, K. M.; Busch, D. H.; et al. (2007). Necrotic tumor cell death in vivo impairs tumor-specific immune responses. The Journal of Immunology, 178(3), 1573-1580.
85. Iiizumi, M.; Mohinta, S.; Bandyopadhyay, S.; & Watabe, K. (2007). Tumor-endothelial cell interactions: therapeutic potential. Microvascular Research, 74(2-3), 114-120.
86. Miles, F. L.; Pruitt, F. L.; van Golen, K. L.; & Cooper, C. R. (2008). Stepping out of the flow: capillary extravasation in cancer metastasis. Clinical & Experimental Metastasis, 25(4), 305-324.
87. van den Brule, F. A.; Buicu, C.; Baldet, M.; Sobel, M. E.; Cooper, D. N.; Marschal, P.; et al. (1995). Galectin-1 modulates human melanoma cell adhesion to laminin. Biochemical and Biophysical Research Communications, 209(2), 760-767.
88. Perillo, N. L.; Marcus, M. E.; & Baum, L. G. (1998). Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death. Journal Molecular Medica (Berliner), 76(6), 402-412.
89. Ito, K.; & Ralph, S. J. (2012). Inhibiting galectin-1 reduces murine lung metastasis with increased CD4(+) and CD8 (+) T cells and reduced cancer cell adherence. Clinical and Experimental Metastasis. doi: 10.1007/s10585-012- 9471-7.
90. Elola, M. T.; Wolfenstein-Todel, C.; Troncoso, M. F.; Vasta, G. R.; & Rabinovich, G. A. (2007). Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival. Cellular and Molecular Life Sciences, 64(13), 1679-1700.
91. + T cells and reduced cancer cell adherence. Clinical and Experimental Metastasis.
92. Kuo, P. L.; Huang, M. S.; Cheng, D. E.; Hung, J. Y.; Yang, C. J.; & Chou, S. H. (2012). Lung cancer-derived galectin-1 enhances tumorigenic potentiation of tumor associated dendritic cells by expressing HB-EGF. Journal of Biological Chemistry, 23;287(13):9753-9764.
93. Huang, E. Y.; Chen, Y. F.; Chen, Y. M.; Lin, I. H.; Wang, C. C.; Su, W. H.; et al. (2012). A novel radioresistant mechanism of galectin-1 mediated by H-Ras-dependent pathways in cervical cancer cells. Cell Death Disease, 3, e251.
94. Cho, H. J.; Jeong, H. G.; Lee, J. S.; Woo, E. R.; Hyun, J. W.; Chung, M. H.; et al. (2002). Oncogenic H-Ras enhances DNA repair through the Ras/phosphatidylinositol 3-kinase/Rac1 pathway in NIH3T3 cells. Evidence for association with reactive oxygen species. The Journal of Biological Chemistry, 277(22), 19358-19366.
95. Hancock, J. F. (2003). Ras proteins: different signals from different locations. Nature Reviews Molecular Cell Biology, 4(5), 373-384.
96. Rotblat, B.; Niv, H.; Andre, S.; Kaltner, H.; Gabius, H. J.; & Kloog, Y. (2004). Galectin-1(L11A) predicted from a computed galectin-1 farnesyl-binding pocket selectively inhibits Ras-GTP. Cancer Research, 64(9), 3112-3118.
97. Paz, A.; Haklai, R.; Elad-Sfadia, G.; Ballan, E.; & Kloog, Y. (2001). Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene, 20(51), 7486-7493.
98. Cumpstey, I.; Sundin, A.; Leffler, H.; & Nilsson, U. J. (2005). C2-symmetrical thiodigalactoside bis-benzamido derivatives as high-affinity inhibitors of galectin-3: efficient lectin inhibition through double arginine-arene interactions. Angewandte Chemie (International Ed. in English), 44(32), 5110-5112.
99. Cumpstey, I.; Salomonsson, E.; Sundin, A.; Leffler, H.; & Nilsson, U. J. (2007). Studies of arginine-arene interactions through synthesis and evaluation of a series of galectin-binding aromatic lactose esters. Chembiochem, 8(12), 1389-1398.
100. Collins, P. M.; Oberg, C. T.; Leffler, H.; Nilsson, U. J.; & Blanchard, H. (2012). Taloside inhibitors of Galectin-1 and Galectin-3. Chemical Biology Drug Design, 79, 339-346.
101. Brandwijk, R. J.; Dings, R. P.; van der Linden, E.; Mayo, K. H.; Thijssen, V. L.; & Griffioen, A. W. (2006). Anti-angiogenesis and anti-tumor activity of recombinant anginex. Biochemical and Biophysical Research Communications, 349(3), 1073-1078.
102. Brandwijk, R. J.; Mulder, W. J.; Nicolay, K.; Mayo, K. H.; Thijssen, V. L.; & Griffioen, A. W. (2007). Anginex-conjugated liposomes for targeting of angiogenic endothelial cells. Bioconjugate Chemistry, 18(3), 785-790.
103. Griffioen, A. W.; van der Schaft, D. W.; Barendsz-Janson, A. F.; Cox, A.; Struijker Boudier, H. A.; Hillen, H. F.; et al. (2001). Anginex, a designed peptide that inhibits angiogenesis. The Biochemical Journal, 354(Pt 2), 233-242.
104. Dings, R. P.; van der Schaft, D. W.; Hargittai, B.; Haseman, J.; Griffioen, A. W.; & Mayo, K. H. (2003). Anti-tumor activity of the novel angiogenesis inhibitor anginex. Cancer Letters, 194(1), 55-66.
105. Salomonsson, E.; Thijssen, V. L.; Griffioen, A. W.; Nilsson, U. J.; & Leffler, H. (2011). The anti-angiogenic peptide anginex greatly enhances galectin-1 binding affinity for glycoproteins. The Journal of Biological Chemistry, 286(16), 13801-13804.
106. Pienta, K. J.; Naik, H.; Akhtar, A.; Yamazaki, K.; Replogle, T. S.; Lehr, J.; et al. (1995). Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. Journal of the National Cancer Institute, 87(5), 348-353.
107. Wang, Y.; Nangia-Makker, P.; Balan, V.; Hogan, V.; & Raz, A. (2010). Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment. Cell Death Dis, 1, e101.
108. Liu, H. Y.; Huang, Z. L.; Yang, G. H.; Lu, W. Q.; & Yu, N. R. (2008). Inhibitory effect of modified citrus pectin on liver metastases in a mouse colon cancer model. World Journal of Gastroenterology, 14(48), 7386-7391.
109. Miller, M. C.; Klyosov, A.; & Mayo, K. H. (2011). Structural Features for alpha-galactomannan binding to galectin-1. Glycobiology
110. Cedeno-Laurent, F.; Opperman, M. J.; Barthel, S. R.; Hays, D.; Schatton, T.; Zhan, Q.; et al. (2012). Metabolic inhibition of galectin-1-binding carbohydrates accentuates antitumor immunity. Journal Investment Dermatology, 132, 410-420.
111. Hirabayashi, J.; Hashidate, T.; Arata, Y.; Nishi, N.; Nakamura, T.; Hirashima, M.; et al. (2002). Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochimica et Biophysica Acta, 1572(2-3), 232-254.
112. Pace, K. E.; Lee, C.; Stewart, P. L.; & Baum, L. G. (1999). Restricted receptor segregation into membrane microdomains occurs on human T cells during apoptosis induced by galectin-1. The Journal of Immunology, 163(7), 3801-3811.
113. Lau, K. S.; & Dennis, J. W. (2008). N-Glycans in cancer progression. Glycobiology, 18(10), 750-760.
114. Lange, T.; Ullrich, S.; Müller, I.; Nentwich, M. F.; Stübke, K.; Feldhaus, S.; et al. (2012). Human prostate cancer in a clinically relevant xenograft mouse model: identification of β(1,6)-branched oligosaccharides as a marker of tumor progression. Clinical Cancer Research, 18(5), 1-10.
115. Wong, C. S.; Sceneay, J. E.; House, C. M.; Halse, H. M.; Liu, M. C.; George, J.; et al. (2012). Vascular normalization by loss of Siah2-/- results in increased chemotherapeutic efficacy. Cancer Research, 72, 1694-1704.
116. Amano, M.; Suzuki, M.; Andoh, S.; Monzen, H.; Terai, K.; Williams, B.; et al. (2007). Antiangiogenesis therapy using a novel angiogenesis inhibitor, anginex, following radiation causes tumor growth delay. International Journal of Clinical Oncology, 12(1), 42-47.
117. Dings, R. P.; Yokoyama, Y.; Ramakrishnan, S.; Griffioen, A. W.; & Mayo, K. H. (2003). The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin. Cancer Research, 63(2), 382-385.
118. Dings, R. P.; Van Laar, E. S.; Loren, M.; Webber, J.; Zhang, Y.; Waters, S. J.; et al. (2010). Inhibiting tumor growth by targeting tumor vasculature with galectin-1 antagonist anginex conjugated to the cytotoxic acylfulvene, 6-hydroxylpropylacylfulvene. Bioconjugate Chemistry, 21(1), 20-27.
119. He, J.; & Baum, L. G. (2006). Endothelial cell expression of galectin-1 induced by prostate cancer cells inhibits T-cell transendothelial migration. Laboratory Investigation, 86(6), 578-590.
120. Stannard, K. A.; Collins, P. M.; Ito, K.; Sullivan, E. M.; Scott, S. A.; Gabutero, E.; et al. (2010). Galectin inhibitory disaccharides promote tumour immunity in a breast cancer model. Cancer Letters, 299(2), 95-110.
121. Lahm, H.; Andre, S.; Hoeflich, A.; Fischer, J. R.; Sordat, B.; Kaltner, H.; et al. (2001). Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures. Journal of Cancer Research and Clinical Oncology, 127(6), 375-386.
122. Kageshita, T.; Kashio, Y.; Yamauchi, A.; Seki, M.; Abedin, M. J.; Nishi, N.; et al. (2002). Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance. International Journal of Cancer, 99(6), 809-816.
123. Mathieu, V.; Le Mercier, M.; De Neve, N.; Sauvage, S.; Gras, T.; Roland, I.; et al. (2007). Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model. The Journal of Investigative Dermatology, 127(10), 2399-2410.
124. Le Mercier, M.; Lefranc, F.; Mijatovic, T.; Debeir, O.; Haibe-Kains, B.; Bontempi, G.; et al. (2008). Evidence of galectin-1 involvement in glioma chemoresistance. Toxicology and Applied Pharmacology, 229(2), 172-183.
125. Alves, P. M.; Godoy, G. P.; Gomes, D. Q.; Medeiros, A. M.; de Souza, L. B.; da Silveira, E. J.; et al. (2011). Significance of galectins-1, -3, -4 and -7 in the progression of squamous cell carcinoma of the tongue. Pathology Research and Practice, 207(4), 236-240.
126. Rubinstein, N.; Alvarez, M.; Zwirner, N. W.; Toscano, M. A.; Ilarregui, J. M.; Bravo, A.; et al. (2004). Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; a potential mechanism of tumor-immune privilege. Cancer Cell, 5(3), 241-251.
127. Cooper, D.; Norling, L. V.; & Perretti, M. (2008). Novel insights into the inhibitory effects of galectin-1 on neutrophil recruitment under flow. Journal of Leukocyte Biology, 83(6), 1459-1466.
128. Iurisci, I.; Tinari, N.; Natoli, C.; Angelucci, D.; Cianchetti, E.; & Iacobelli, S. (2000). Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clinical Cancer Research, 6(4), 1389-1393.
129. Paret, C.; Hildebrand, D.; Weitz, J.; Kopp-Schneider, A.; Kuhn, A.; Beer, A.; et al. (2007). C4.4A as a candidate marker in the diagnosis of colorectal cancer. British Journal of Cancer, 97(8), 1156.
130. Righi, A.; Jin, L.; Zhang, S.; Stilling, G.; Scheithauer, B. W.; Kovacs, K.; et al. (2010). Identification and consequences of galectin-3 expression in pituitary tumors. Molecular and Cellular Endocrinology, 326(1-2), 8-14.
131. Nagy, N.; Legendre, H.; Engels, O.; Andre, S.; Kaltner, H.; Wasano, K.; et al. (2003). Refined prognostic evaluation in colon carcinoma using immunohistochemical galectin fingerprinting. Cancer, 97(8), 1849-1858.
132. Kobayashi, T.; Shimura, T.; Yajima, T.; Kubo, N.; Araki, K.; Tsutsumi, S.; et al. (2011). Transient gene silencing of galectin-3 suppresses pancreatic cancer cell migration and invasion through degradation of beta-catenin. International Journal of Cancer, 129(12), 2775-2786.
133. Ahmed, H.; Cappello, F.; Rodolico, V.; & Vasta, G. R. (2009). Evidence of heavy methylation in the galectin 3 promoter in early stages of prostate adenocarcinoma: development and validation of a methylated marker for early diagnosis of prostate cancer. Translational Oncology, 2(3), 146-156.
134. van den Brule, F. A.; Waltregny, D.; Liu, F. T.; & Castronovo, V. (2000). Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression. International Journal of Cancer, 89(4), 361-367.
135. Peng, W.; Wang, H. Y.; Miyahara, Y.; Peng, G.; & Wang, R. F. (2008). Tumor-associated galectin-3 modulates the function of tumor-reactive T cells.
136. Endo, K.; Kohnoe, S.; Tsujita, E.; Watanabe, A.; Nakashima, H.; Baba, H.; et al. (2005). Galectin-3 expression is a potent prognostic marker in colorectal cancer. Anticancer Research, 25(4), 3117-3121.
137. Kobayashi, T.; Shimura, T.; Yajima, T.; Kubo, N.; Araki, K.; Wada, W.; et al. (2011). Transient silencing of galectin-3 expression promotes both in vitro and in vivo drug-induced apoptosis of human pancreatic carcinoma cells. Clinical & Experimental Metastasis, 28(4), 367-376.
138. Cheong, T. C.; Shin, J. Y.; & Chun, K. H. (2010). Silencing of galectin-3 changes the gene expression and augments the sensitivity of gastric cancer cells to chemotherapeutic agents. Cancer Science, 101(1), 94-102.
139. Merseburger, A. S.; Kramer, M. W.; Hennenlotter, J.; Simon, P.; Knapp, J.; Hartmann, J. T.; et al. (2008). Involvement of decreased galectin-3 expression in the pathogenesis and progression of prostate cancer. The Prostate, 68(1), 72-77.
140. Pacis, R. A.; Pilat, M. J.; Pienta, K. J.; Wojno, K.; Raz, A.; Hogan, V.; et al. (2000). Decreased galectin-3 expression in prostate cancer. The Prostate, 44(2), 118-123.
141. Wang, Y. G.; Kim, S. J.; Baek, J. H.; Lee, H. W.; Jeong, S. Y.; & Chun, K. H. (2012). Galectin-3 increases the motility of mouse melanoma cells by regulating MMP-1 expression. Experimental & Molecular Medicine (in press)
142. Heinzelmann-Schwarz, V. A.; Gardiner-Garden, M.; Henshall, S. M.; Scurry, J. P.; Scolyer, R. A.; Smith, A. N.; et al. (2006). A distinct molecular profile associated with mucinous epithelial ovarian cancer. British Journal of Cancer, 94(6), 904-913.
143. Heinzelmann-Schwarz, V. A.; Scolyer, R. A.; Scurry, J. P.; Smith, A. N.; Gardiner-Garden, M.; Biankin, A. V.; et al. (2007). Low meprin alpha expression differentiates primary ovarian mucinous carcinoma from gastrointestinal cancers that commonly metastasise to the ovaries. Journal of Clinical Pathology, 60(6), 622-626.
144. Demers, M.; Biron-Pain, K.; Hebert, J.; Lamarre, A.; Magnaldo, T.; & St-Pierre, Y. (2007). Galectin-7 in lymphoma: elevated expression in human lymphoid malignancies and decreased lymphoma dissemination by antisense strategies in experimental model. Cancer Research, 67(6), 2824-2829.
145. Moisan, S.; Demers, M.; Mercier, J.; Magnaldo, T.; Potworowski, E. F.; & St-Pierre, Y. (2003). Upregulation of galectin-7 in murine lymphoma cells is associated with progression toward an aggressive phenotype. Leukemia, 17(4), 751-759.
146. Liang, X. Q.; Cao, E. H.; Zhang, Y.; & Qin, J. F. (2003). P53-induced gene 11 (PIG11) involved in arsenic trioxide-induced apoptosis in human gastric cancer MGC-803 cells. Oncology Reports, 10(5), 1265-1269.
147. Nagy, N.; Bronckart, Y.; Camby, I.; Legendre, H.; Lahm, H.; Kaltner, H.; et al. (2002). Galectin-8 expression decreases in cancer compared with normal and dysplastic human colon tissue and acts significantly on human colon cancer cell migration as a suppressor. Gut, 50(3), 392-401.
148. Klibi, J.; Niki, T.; Riedel, A.; Pioche-Durieu, C.; Souquere, S.; Rubinstein, E.; et al. (2009). Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells. Blood, 113(9), 1957-1966.
149. Yamauchi, A.; Kontani, K.; Kihara, M.; Nishi, N.; Yokomise, H.; & Hirashima, M. (2006). Galectin-9, a novel prognostic factor with antimetastatic potential in breast cancer. The Breast Journal, 12(5 Suppl 2), S196-S200.
150. Irie, A.; Yamauchi, A.; Kontani, K.; Kihara, M.; Liu, D.; Shirato, Y.; et al. (2005). Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clinical Cancer Research, 11(8), 2962-2968.
151. Yang, R. Y.; Hsu, D. K.; Yu, L.; Ni, J.; & Liu, F. T. (2001). Cell cycle regulation by galectin-12, a new member of the galectin superfamily. The Journal of Biological Chemistry, 276(23), 20252-20260.
152. Barthel, S. R.; Antonopoulos, A.; Cedeno-Laurent, F.; Schaffer, L.; Hernandez, G.; Patil, S. A.; et al. (2011). Peracetylated 4-fluoro-glucosamine reduces the content and repertoire of N- and O-glycans without direct incorporation. The Journal of Biological Chemistry, 286(24), 21717-21731.